Applied Clinical Trials
The financial aspect of standard of care in patient treatment has become a major issue for many companies conducting clinical research. Many industry monitors, self-appointed and otherwise, have highlighted the issue of payments to physicians by pharmaceutical companies, including the fair market payment of clinical grants, as possibly influencing physician behavior. Subjects in later phase clinical research must have the malady being treated in the clinical trial. Consequently, many of the treatments these patients receive would and should be covered by third-party payers, typically government agencies or commercial insurance companies.
The financial aspect of standard of care in patient treatment has become a major issue for many companies conducting clinical research. Many industry monitors, self-appointed and otherwise, have highlighted the issue of payments to physicians by pharmaceutical companies, including the fair market payment of clinical grants, as possibly influencing physician behavior. Subjects in later phase clinical research must have the malady being treated in the clinical trial. Consequently, many of the treatments these patients receive would and should be covered by third-party payers, typically government agencies or commercial insurance companies.
Double Dip: Third-Party and Pharma
In addition to questions of fair market value, senior clinical development management is simply looking for better ways to deal with rapidly increasing drug development costs. One way is to avoid double payments for medical procedures that are covered by third-party payers. A review of over 100 current protocols1 demonstrates that, while companies are introducing standard of care considerations into their clinical grants, a substantial amount of potential payment overlap still exists. An additional 22% of clinical grants, beyond what pharmaceutical companies already consider as standard of care, is usually covered by these third-party payers. Standard of care is no longer a subjective measure, but rather what physicians are paid to treat a patient for a specific indication according to actual payment records.2 Moreover, a large percentage, 80%, of this payment overlap takes place for less expensive procedures, that is, procedures costing less than $1000,—TTC (for more information, please contact help@ttc-llc.com).
1. Subscribers to GrantPlan conduct over 76% of all clinical trials http://ClinicalTrials.gov; March 1, 2010.
2. Trialytics payments data covering over 800 million payment records from commercial insurance companies, Medicare and Medicaid.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.